# Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

> **NCT00979862** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Neoplasm

## Interventions

- **DRUG:** Cediranib Maleate
- **DRUG:** Cilengitide
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00979862
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-05
- **Final completion:** 2014-02
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979862, "Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00979862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*